Kombinovaná fágová terapie infekcí PVL-pozitivními kmeny Staphylococcus aureus
| Title in English | Combination phage therapy for infections with PVL-positive strains of Staphylococcus aureus |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Staphylococcus aureus is one of the major human pathogens that mainly causes wound and soft tissue infections. The virulence of some strains is enhanced by the production of toxins such as Panton-Valentine leukocidin (PVL) or biofilm. It is present as a commensal on the nasal mucosa and elsewhere in the body in a proportion of the population. Its presence is a risk factor requiring eradication in defined cases, e.g. before cardiac surgery or in recurrent infections with PVL-producing strains of S. aureus. Nasal application of mupirocin combined with whole-body washing with antiseptics and environmental disinfection is used as part of decolonisation. However, this decolonisation fails in up to 30% of patients and must be repeated. Bacteriophages serve as an alternative biofilm-penetrating therapy that can be combined with antibiotic therapy, and we therefore tested their interaction. In our study, we investigated the susceptibility of 17 PVL-positive S. aureus strains to the Kayvirus phage 812K1/420 and the interaction between this phage and mupirocin. All S. aureus strains tested were sensitive to mupirocin, MIC50 = MIC90 = 0.125 mg/L. One strain was resistant to phage, the others were sensitive, MIC50 1x106 PFU/mL and MIC90107 PFU/mL. A checkerboard assay was used to compare the interaction between mupirocin and phage and the interaction was determined. The assay resulted in inhibition of phage when administered with mupirocin, with a decrease in efficacy of up to three orders of magnitude. The MIC of the antibiotic was not affected by the application of phage. Reciprocal antagonism may not indicate clinical treatment failure, but the amount of phage administered should be increased when combining phage 812K1/420 with mupirocin. |
| Related projects: |